Orthofix Medical Inc. (NASDAQ: OFIX) saw its stock price surge 5.67% in pre-market trading on Tuesday, following the release of its impressive third-quarter financial results. The medical device company specializing in spine and orthopedic solutions outperformed analyst expectations, demonstrating robust growth across key metrics.

The company reported Q3 net sales of $205.6 million, a 5% year-over-year increase, surpassing the consensus estimate of $200 million. Adjusted EBITDA for the quarter reached $24.6 million, marking a significant 28.2% year-over-year growth and exceeding analyst projections of $20.1 million. Orthofix also posted a strong gross margin of 72.2% for the quarter.

Driving this performance were several factors, including an 8% growth in U.S. Spine Fixation net sales, bolstered by the 7D FLASH™ navigation technology. The Bone Growth Therapies segment saw a 6% increase in net sales, while U.S. Orthopedics net sales jumped by an impressive 19%, aided by the launch of TrueLok™ Elevate. In light of these results, Orthofix has narrowed its full-year 2025 net sales guidance to $810-$814 million and raised the low end of its adjusted EBITDA guidance to $84-$86 million, signaling continued confidence in its growth trajectory.